Reference products and why people stop using them — pediatric obstructive sleep apnea testing

1. Summary

FDA 510(k) records place at least 56 home sleep apnea test (HSAT) devices in product code MNR ("Ventilatory Effort Recorder") cleared since 2016-09-04, and an indication for use reaching below age 18 is the exception rather than the rule among them [1]. Exactly two devices in that roster carry any sub-18 language: the SNAP Diagnostics SAM Model 9-10000, cleared with an indication naming both pediatric and adult patients [2], and the WatchPAT ONE, whose indication splits by parameter — one output restricted to age 17 and older, the rest extended to 12 and older [3]. Six devices cleared between 2019 and 2025 that this report read directly each carry an adult-only indication, one of them restricted to age 22 and older [4][5][6][7][8][9]. The one completed device-specific validation of a home sleep test in adolescents registered on ClinicalTrials.gov has posted results that raise, rather than settle, questions about the device's accuracy and completion rate in that age band, detailed with their sponsor in Section 3 [10]. A second, larger pediatric HSAT-versus-PSG comparison trial remains open with no results posted [11]. One enforcement action — a firmware-related position-detection recall — exists in this product code in the last decade and is unrelated to pediatric use [1].

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

The device landscape behind the incumbent's would-be replacement

FDA's openFDA device/510(k) database lists 56 clearances in product code MNR decided between 2016-09-04 and 2026-09-02, the product code covering ventilatory-effort-recording HSAT devices generally, including SNAP Diagnostics, WatchPAT, ApneaLink, Wesper, Onera, Huxley SANSA, Belun and others [1]. This is the pool from which any pediatric-alternative-to-PSG device would have to be drawn or against which a new entrant would be compared, and it is overwhelmingly an adult product line: this report read the indications-for-use text of eight of the 56 clearances directly (via each device's 510(k) summary), and found sub-18 language in exactly two.

The two devices with any pediatric-inclusive labeling

SNAP Diagnostics SAM Model 9-10000 (K240100, decided 2024-06-04). Read directly from the 510(k) summary: "Both pediatric and adult patients may be tested. Use of this device must be under the direct supervision of a qualified adult (parent or guardian) or health care practitioner trained in the use of the Snap Diagnostics SAM Model 9-10000 device" [2]. The same summary states the device "is not intended as a substitute for full polysomnography when additional parameters such as sleep stages or EEG activity are required" [2].

WatchPAT ONE (K223675, decided 2023-01-06). Read directly from the 510(k) summary: "PAHIc is indicated for use in patients 17 years and older. All other parameters are indicated for 12 years and older" [3] — a more granular split than a flat "12 and older" line, since it withholds the device's central-apnea-hypopnea index specifically from the 12-16 band while extending its other outputs (respiratory disturbance index, apnea-hypopnea index, sleep staging) to that band.

The adult-only majority, read directly

Six devices cleared in the same product code between 2019 and 2025, read directly from their 510(k) summaries, each restrict use to adults: Huxley SANSA ("adults suspected of sleep apnea") [4], Belun Sleep System BLS-100 ("adult patients suspected of sleep apnea") [5], Happy Health Home Sleep Test ("individuals who are 22 years of age or older") [6], Wesper Cassie ("inform or drive clinical management for adults") [7], and SomnaPatch ("intended for adult use") [8][9]. None of these six mentions a pediatric or adolescent population in the language retrieved.

The one completed pediatric-adjacent validation trial

ClinicalTrials.gov NCT03748771, "Validation of ApneaLink Air Home Sleep Testing in the Diagnosis of Obstructive Sleep Apnea in Adolescent Children," sponsor ResMed, status COMPLETED, enrolled 20 participants ages 12-17 (actual, mean age 14.5 years), comparing the ApneaLink Air home test (HST) against same-window in-lab ApneaLink Lab Testing (ALT) and polysomnography (PSG) [10]. The posted results, read directly from the registry's results module: mean apnea-hypopnea index (AHI) was 6.2 events/hour from HST versus 18.6 events/hour from PSG in the same cohort — roughly a third — and mean oxygen desaturation index (ODI) was 10.9 (HST) versus 13.5 (PSG) [sponsor-reported, 10]. A technically successful HST recording (meeting the study's own artifact/signal-duration threshold) was obtained in 15 of 20 participants (75%), versus 17 of 20 for the lab-based ALT comparator [sponsor-reported, 10]. On the study's own patient-preference question ("Do you prefer HST over PSG?"), 12 of 20 participants answered yes, 4 answered no, and 1 reported no difference [sponsor-reported, 10]. ApneaLink Air itself carries only an adult clearance (K070263/K143272); this trial is a sponsor-run adolescent validation of an adult-cleared device, not evidence behind a pediatric indication.

The one open pediatric HSAT trial

ClinicalTrials.gov NCT05382754, "Home Apnea Testing in CHildren Trial," sponsor Children's Hospital of Philadelphia, status RECRUITING, no results posted, randomized crossover design, ages 5-12, enrollment target 317 (estimated, a target the sponsor registered rather than a count of anyone enrolled) [11]. Its outcomes include OSA-diagnosis concordance between HSAT and PSG, therapeutic-decision concordance, correlation of obstructive AHI between the two modalities, and a preference question — none of which has reported [sponsor-reported, 11].

Enforcement history in this product code

One device recall exists in product code MNR in the last decade: Z-0031-2022, Nox Medical Nox T3s Recorder, status Terminated, initiated 2021-09-07, "Error in the device firmware results in the inaccurate detection of device position," related to 510(k) K082113 [1]. Nothing in the recall record ties it to pediatric use specifically.

4. Sources

[1] openFDA device/510(k), device/classification and device/recall databases, product code MNR "Ventilatory Effort Recorder," regulation 21 CFR 868.2375 per the classification record (continuously updated; queried window 2016-09-04 to 2026-09-02; accessed 2026-09-01). 21 CFR 868.2375 — https://api.fda.gov/device/510k.json?search=product_code:MNR [federal-registry] [2] FDA 510(k) Summary K240100 — SNAP Diagnostics SAM Model 9-10000, Snap Diagnostics, LLC (decided 2024-06-04; accessed 2026-09-01). K240100 — https://www.accessdata.fda.gov/cdrh_docs/pdf24/K240100.pdf [federal-registry] [3] FDA 510(k) Summary K223675 — WatchPAT ONE (WP1), Itamar Medical, Ltd. (decided 2023-01-06; accessed 2026-09-01). K223675 — https://www.accessdata.fda.gov/cdrh_docs/pdf22/K223675.pdf [federal-registry] [4] FDA 510(k) Summary K250882 — Huxley Home Sleep Apnea Test (SANSA), Huxley Medical (decided 2025-10-29; accessed 2026-09-01). K250882 — https://www.accessdata.fda.gov/cdrh_docs/pdf25/K250882.pdf [federal-registry] [5] FDA 510(k) Summary K222579 — Belun Sleep System BLS-100, Belun Technology Company Limited (decided 2023-02-23; accessed 2026-09-01). K222579 — https://www.accessdata.fda.gov/cdrh_docs/pdf22/K222579.pdf [federal-registry] [6] FDA 510(k) Summary K242224 — Happy Health Home Sleep Test, Happy Health, Inc. (decided 2025-06-18; accessed 2026-09-01). K242224 — https://www.accessdata.fda.gov/cdrh_docs/pdf24/K242224.pdf [federal-registry] [7] FDA 510(k) Summary K252628 — Cassie, Wesper, Inc. (decided 2025-04-27; accessed 2026-09-01). K252628 — https://www.accessdata.fda.gov/cdrh_docs/pdf25/K252628.pdf [federal-registry] [8] FDA 510(k) Summary K183625 — SomnaPatch, Respironics, Inc. (decided 2019-10-18; accessed 2026-09-01). K183625 — https://www.accessdata.fda.gov/cdrh_docs/pdf18/K183625.pdf [federal-registry] [9] openFDA device/510(k) k_number=K183625 record confirming decision date and applicant for SomnaPatch (decided 2019-10-18; accessed 2026-09-01). K183625 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K183625 [federal-registry] [10] ClinicalTrials.gov NCT03748771 — "Validation of ApneaLink Air Home Sleep Testing in the Diagnosis of Obstructive Sleep Apnea in Adolescent Children," sponsor ResMed, results posted 2021-11-15 (accessed 2026-09-01). NCT03748771 — https://clinicaltrials.gov/study/NCT03748771 [trial-registry] [11] ClinicalTrials.gov NCT05382754 — "Home Apnea Testing in CHildren Trial," sponsor Children's Hospital of Philadelphia, status RECRUITING, last update 2026-04-21 (accessed 2026-09-01). NCT05382754 — https://clinicaltrials.gov/study/NCT05382754 [trial-registry]

5. Sourcing & Gaps

Well established: The count and product-code composition of the HSAT clearance roster [1] and the exact indications-for-use text of the eight devices read directly [2][3][4][5][6][7][8][9] are each drawn straight from a single federal registry record — the canonical source for that fact — and are stated plainly rather than marked, consistent with how this domain's dossier already treats individually-verified registry entries.

Thin: Every quantitative finding from NCT03748771 (AHI/ODI comparison, completion rate, preference split) rests on one sponsor-run trial's own posted results, carries [sponsor-reported] throughout, and has not been corroborated by an independent publication — a PubMed search for a published report of the same trial ("ApneaLink Air adolescent home sleep test validation") returned zero records as of this pass. The claim that adult-only labeling is the norm across the full 56-device roster rests on a spot check of eight named devices, not an exhaustive read of all 56 summaries; the eight were chosen to include both the oldest and most recent clearances and both of the two devices with any pediatric-inclusive language, but the remaining 48 have not been individually read this pass.

Rescoped from class 3: None in this report. The one place a class-3 question appears adjacent to this material is NCT03748771's and NCT05382754's own "prefer HSAT to PSG" outcome questions, which are registry-native revealed-behaviour proxies already built into those trials rather than a rescoping performed by this report.

Out of scope: MAUDE complaint/failure-mode narratives for any device named here (no connector reaches MAUDE in this repo). Device pricing for any HSAT device (no connector and no pricing page was retrieved this pass). Current commercial-distribution status of any device named here — a 510(k) clearance record does not itself establish whether a device remains on the market, and no connector in this repo checks distribution status.

Not searched vs. not found: A post-2019 published corroboration of NCT03748771's results was searched for directly and not found (zero PubMed records for the query above). Full indications-for-use text for the remaining 48 of 56 devices in product code MNR was not searched this pass. Whether any state or private payer treats WatchPAT's 12+ or SNAP's pediatric label differently in coverage was not searched.

[inference] The adult-only pattern across the six directly-read 2019-2025 clearances, set against the two devices with sub-18 language decided in 2023-2024, suggests manufacturers treat a pediatric indication as an added claim requiring its own supporting data rather than a default extension of an adult clearance — a synthesis of this report's own reading, not stated by any cited source.

6. Claim Candidates